605507 国邦医药
交易中 08-13 09:52:40
资讯
新帖
简况
每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿
证券之星 · 08-09
每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿
8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股
证券之星 · 08-07
8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股
国邦医药涨5.40%,西南证券二日前给出“买入”评级
证券之星 · 08-07
国邦医药涨5.40%,西南证券二日前给出“买入”评级
西南证券:给予国邦医药买入评级
证券之星 · 08-05
西南证券:给予国邦医药买入评级
股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》
证券之星 · 08-05
股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》
国邦医药(605507)披露股份回购进展公告,8月3日股价下跌1.35%
证券之星 · 08-03
国邦医药(605507)披露股份回购进展公告,8月3日股价下跌1.35%
国邦医药(605507)2026年中报简析:增收不增利
证券之星 · 08-02
国邦医药(605507)2026年中报简析:增收不增利
国邦医药(605507)6月30日股东户数2.09万户,较上期增加3.89%
证券之星 · 08-01
国邦医药(605507)6月30日股东户数2.09万户,较上期增加3.89%
国邦医药(605507)披露2026年半年度报告,7月31日股价下跌0.37%
证券之星 · 07-31
国邦医药(605507)披露2026年半年度报告,7月31日股价下跌0.37%
国邦医药(605507.SH)发布半年度业绩,归母净利润3.41亿元,同比下降25.07%
智通财经 · 07-31
国邦医药(605507.SH)发布半年度业绩,归母净利润3.41亿元,同比下降25.07%
每周股票复盘:国邦医药(605507)累计回购1.32%股份
证券之星 · 07-05
每周股票复盘:国邦医药(605507)累计回购1.32%股份
国邦医药(605507)披露股份回购进展公告,7月2日股价上涨1.88%
证券之星 · 07-02
国邦医药(605507)披露股份回购进展公告,7月2日股价上涨1.88%
每周股票复盘:国邦医药(605507)回购股份达1.07%
证券之星 · 06-28
每周股票复盘:国邦医药(605507)回购股份达1.07%
国邦医药(605507)披露回购公司股份比例达1%暨回购进展公告,6月24日股价下跌0.99%
证券之星 · 06-24
国邦医药(605507)披露回购公司股份比例达1%暨回购进展公告,6月24日股价下跌0.99%
每周股票复盘:国邦医药(605507)子公司投2.5亿参与基金
证券之星 · 06-20
每周股票复盘:国邦医药(605507)子公司投2.5亿参与基金
国邦医药(605507)披露全资子公司参与投资股权投资基金公告,6月16日股价下跌2.31%
证券之星 · 06-16
国邦医药(605507)披露全资子公司参与投资股权投资基金公告,6月16日股价下跌2.31%
6月10日国邦医药涨5.14%,鹏华优质治理LOF基金重仓该股
证券之星 · 06-10
6月10日国邦医药涨5.14%,鹏华优质治理LOF基金重仓该股
国邦医药涨5.14%,开源证券一个月前给出“买入”评级
证券之星 · 06-10
国邦医药涨5.14%,开源证券一个月前给出“买入”评级
国邦医药最新公告:取得金融机构不超1.8亿元回购贷款承诺函
证券之星 · 06-01
国邦医药最新公告:取得金融机构不超1.8亿元回购贷款承诺函
每周股票复盘:DR国邦医(605507)国邦医药推1至2亿元回购计划
证券之星 · 05-31
每周股票复盘:DR国邦医(605507)国邦医药推1至2亿元回购计划
加载更多
公司概况
公司名称:
国邦医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2021-08-02
主营业务:
国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、“优秀院士专家工作站”、第一批浙江省制造业单项冠军企业等荣誉称号。
发行价格:
32.57
{"stockData":{"symbol":"605507","market":"SH","secType":"STK","nameCN":"国邦医药","latestPrice":15.44,"timestamp":1786585960000,"preClose":15.64,"halted":0,"volume":2197520,"delay":0,"changeRate":-0.0128,"floatShares":782000000,"shares":782000000,"eps":0.9032,"marketStatus":"交易中","change":-0.2,"latestTime":"08-13 09:52:40","open":15.61,"high":15.64,"low":15.32,"amount":33927700,"amplitude":0.0205,"askPrice":15.44,"askSize":49,"bidPrice":15.43,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.9032,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786591800000},"marketStatusCode":2,"adr":0,"adjPreClose":15.64,"symbolType":"stock","openAndCloseTimeList":[[1786584600000,1786591800000],[1786597200000,1786604400000]],"highLimit":17.2,"lowLimit":14.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":782352900,"isCdr":false,"pbRate":1.46,"roa":"--","peRate":17.094774,"roe":"3.96%","epsLYR":1.48,"committee":0.84087,"marketValue":12080000000,"turnoverRate":0.0028,"status":1,"floatMarketCap":12080000000},"requestUrl":"/m/hq/s/605507","defaultTab":"news","newsList":[{"id":"2658673435","title":"每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673435?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:40","pubTimestamp":1786210822,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,国邦医药报收于16.2元,较上周的16.24元下跌0.25%。本周,国邦医药8月3日盘中最高价报16.39元。国邦医药当前最新总市值126.74亿元,在化学制药板块市值排名39/149,在两市A股市值排名1487/5205。本周关注点公司公告汇总:国邦医药已回购股份11,183,416股,占总股本的1.43%,支付金额172,287,559.45元。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615764","title":"8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657615764?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:38","pubTimestamp":1786091923,"startTime":"0","endTime":"0","summary":"证券之星消息,8月7日国邦医药涨5.40%,收盘报16.2元,换手率2.02%,成交量15.84万手,成交额2.53亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为8.55亿元,最新净值1.2994,较上一交易日下跌0.6%,近一年上涨3.62%。鹏华优质治理LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061571","title":"国邦医药涨5.40%,西南证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061571?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:38","pubTimestamp":1786091909,"startTime":"0","endTime":"0","summary":"今日国邦医药涨5.40%,收盘报16.2元。2026年8月5日,西南证券研究员徐卿,赵磐发布了对国邦医药的研报《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,该研报对国邦医药给出“买入”评级。研报中预计2026-2028年EPS分别为1.23元、1.52元、1.75元,对应动态PE分别为13/11/9倍,维持“买入”评级。国邦医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547389","title":"西南证券:给予国邦医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547389?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:55","pubTimestamp":1785934518,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司徐卿,赵磐近期对国邦医药进行研究并发布了研究报告《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,给予国邦医药买入评级。最新盈利预测明细如下:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为21.0。本文数据来源于西南证券股份有限公司,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637565","title":"股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657637565?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:46","pubTimestamp":1785869172,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年7月31日,国邦医药已累计回购股份11,183,416股,占总股本1.43%,支付金额172,287,559.45元。公司公告汇总2026-032 国邦医药关于股份回购进展公告国邦医药集团股份有限公司于2026年5月29日召开董事会,审议通过以集中竞价交易方式回购股份的方案,回购资金总额为1亿元至2亿元,回购价格不超过23元/股,回购期限为2026年5月30日至2027年5月29日,用途为员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656737743","title":"国邦医药(605507)披露股份回购进展公告,8月3日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656737743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656737743?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:38","pubTimestamp":1785767896,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,国邦医药报收于16.02元,较前一交易日下跌1.35%,最新总市值为125.33亿元。该股当日开盘16.0元,最高16.39元,最低15.43元,成交额达9829.91万元,换手率为0.79%。近日,国邦医药发布《关于股份回购进展公告》。截至2026年7月31日,公司已累计回购股份11,183,416股,占总股本的1.43%,回购最高价为16.27元/股,最低价为14.35元/股,已支付总金额172,287,559.45元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588311","title":"国邦医药(605507)2026年中报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588311","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656588311?lang=zh_cn&edition=full","pubTime":"2026-08-02 06:01","pubTimestamp":1785621671,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期国邦医药发布2026年中报。根据财报显示,国邦医药增收不增利。截至本报告期末,公司营业总收入31.42亿元,同比上升3.84%,归母净利润3.41亿元,同比下降25.07%。去年的净利率为13.6%,算上全部成本后,公司产品或服务的附加值高。持有国邦医药最多的基金为鹏华优质治理LOF,目前规模为8.55亿元,最新净值1.2875,较上一交易日上涨1.27%,近一年上涨4.16%。本文数据来源于国邦医药2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656318235","title":"国邦医药(605507)6月30日股东户数2.09万户,较上期增加3.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656318235","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656318235?lang=zh_cn&edition=full","pubTime":"2026-08-01 17:02","pubTimestamp":1785574922,"startTime":"0","endTime":"0","summary":"证券之星消息,近日国邦医药披露,截至2026年6月30日公司股东户数为2.09万户,较3月31日增加781.0户,增幅为3.89%。在化学制药行业个股中,国邦医药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.6万户。从股价来看,2026年3月31日至2026年6月30日,国邦医药区间跌幅为18.03%,在此期间股东户数增加781.0户,增幅为3.89%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100012771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362996","title":"国邦医药(605507)披露2026年半年度报告,7月31日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362996?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:15","pubTimestamp":1785507347,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,国邦医药报收于16.24元,较前一交易日下跌0.37%,最新总市值为127.05亿元。该股当日开盘16.2元,最高16.36元,最低16.01元,成交额达9481.16万元,换手率为0.75%。近日,国邦医药集团股份有限公司披露《2026年半年度报告》。经营活动产生的现金流量净额为454,949,533.71元,同比上升342.23%。加权平均净资产收益率为3.96%,较上年同期减少1.65个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100041749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655579613","title":"国邦医药(605507.SH)发布半年度业绩,归母净利润3.41亿元,同比下降25.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655579613","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655579613?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:18","pubTimestamp":1785493084,"startTime":"0","endTime":"0","summary":"智通财经APP讯,国邦医药 披露2026年半年度报告,报告期公司实现营收31.42亿元,同比增长3.84%;归属于上市公司股东的净利润3.41亿元,同比下降25.07%;扣非净利润3.21亿元,同比下降26.46%;基本每股收益0.44元。上半年,公司持续加强科研攻关,创新业务不断取得突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"国邦医药(605507.SH)发布半年度业绩,归母净利润3.41亿元,同比下降25.07%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649622692","title":"每周股票复盘:国邦医药(605507)累计回购1.32%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2649622692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649622692?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:52","pubTimestamp":1783194732,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,国邦医药报收于15.76元,较上周的14.7元上涨7.21%。本周,国邦医药7月3日盘中最高价报15.95元。6月29日盘中最低价报14.34元,股价触及近一年最低点。国邦医药当前最新总市值123.3亿元,在化学制药板块市值排名40/149,在两市A股市值排名1638/5203。截至2026年6月30日,公司已累计回购股份10,357,275股,占总股本的1.32%,已支付总金额159,885,933.94元,回购均价区间为14.35元/股至16.14元/股。上述回购进展符合相关法规及公司方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648065695","title":"国邦医药(605507)披露股份回购进展公告,7月2日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648065695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648065695?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:46","pubTimestamp":1782985601,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘,国邦医药报收于15.68元,较前一交易日上涨1.88%,最新总市值为122.67亿元。该股当日开盘15.47元,最高15.82元,最低15.4元,成交额达8235.34万元,换手率为0.67%。国邦医药于近日披露《关于股份回购进展公告》。截至2026年6月30日,公司已累计回购股份10,357,275股,占总股本的1.32%,已支付总金额159,885,933.94元,回购均价区间为14.35元/股至16.14元/股。上述回购进展符合相关法规及公司方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200030175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315335","title":"每周股票复盘:国邦医药(605507)回购股份达1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646315335?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:13","pubTimestamp":1782587590,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,国邦医药报收于14.7元,较上周的15.22元下跌3.42%。本周,国邦医药6月24日盘中最高价报15.74元。6月26日盘中最低价报14.66元,股价触及近一年最低点。国邦医药当前最新总市值115.01亿元,在化学制药板块市值排名37/150,在两市A股市值排名1693/5206。截至2026年6月24日,公司已累计回购股份8,401,562股,占总股本的1.07%,成交最高价为16.14元/股,最低价为14.99元/股,已支付总金额130,855,228.28元。上述进展符合相关法规及公司回购方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645118838","title":"国邦医药(605507)披露回购公司股份比例达1%暨回购进展公告,6月24日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645118838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645118838?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:35","pubTimestamp":1782311714,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,国邦医药报收于15.05元,较前一交易日下跌0.99%,最新总市值为117.74亿元。该股当日开盘15.55元,最高15.74元,最低15.01元,成交额达7564.08万元,换手率为0.63%。近日,国邦医药发布《关于回购公司股份比例达1%暨回购进展公告》。截至2026年6月24日,公司已累计回购股份8,401,562股,占总股本的1.07%,成交最高价为16.14元/股,最低价为14.99元/股,已支付总金额130,855,228.28元。上述进展符合相关法规及公司回购方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400044150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644407065","title":"每周股票复盘:国邦医药(605507)子公司投2.5亿参与基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2644407065","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644407065?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:09","pubTimestamp":1781896192,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,国邦医药报收于15.22元,较上周的16.18元下跌5.93%。本周,国邦医药6月15日盘中最高价报16.47元。本周关注点公司公告汇总:全资子公司拟以2.5亿元认购光明国邦基金50%份额,布局高端医药制造与大健康领域。公司公告汇总:国邦医药已回购股份642.5万股,占总股本0.82%,支付金额超1亿元。截至2026年6月16日,公司已累计回购股份6,425,182股,占总股本的0.82%,已支付金额100,934,682元,回购价格区间为15.27元/股至16.14元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000001897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643390753","title":"国邦医药(605507)披露全资子公司参与投资股权投资基金公告,6月16日股价下跌2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643390753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643390753?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:45","pubTimestamp":1781603151,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,国邦医药报收于15.62元,较前一交易日下跌2.31%,最新总市值为122.2亿元。该股当日开盘15.95元,最高15.99元,最低15.58元,成交额达7706.87万元,换手率为0.63%。近日,国邦医药发布《关于全资子公司参与投资股权投资基金的公告》。公告显示,公司全资子公司国邦医药(杭州)股权投资有限公司拟以自有资金25,000万元认购光明国邦(浙江)股权投资合伙企业50.00%的基金份额。本次投资无需提交公司董事会及股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642444949","title":"6月10日国邦医药涨5.14%,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642444949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642444949?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:37","pubTimestamp":1781080652,"startTime":"0","endTime":"0","summary":"证券之星消息,6月10日国邦医药涨5.14%,收盘报16.15元,换手率0.92%,成交量7.22万手,成交额1.14亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共18家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为11.72亿元,最新净值1.2587,较上一交易日下跌0.07%,近一年上涨4.01%。鹏华优质治理LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642449484","title":"国邦医药涨5.14%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642449484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642449484?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:37","pubTimestamp":1781080630,"startTime":"0","endTime":"0","summary":"今日国邦医药涨5.14%,收盘报16.15元。2026年4月17日,开源证券研究员余汝意,阮帅发布了对国邦医药的研报《公司信息更新报告:2026Q1业绩稳健增长,动保原料药迎来周期拐点》,该研报对国邦医药给出“买入”评级。研报中预计2026-2028年公司归母净利润为10.6/12.91/14.67亿元,当前股价对应PE为13.6/11.2/9.9倍,估值性价比高,维持“买入”评级。国邦医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640395689","title":"国邦医药最新公告:取得金融机构不超1.8亿元回购贷款承诺函","url":"https://stock-news.laohu8.com/highlight/detail?id=2640395689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640395689?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:09","pubTimestamp":1780312167,"startTime":"0","endTime":"0","summary":"国邦医药(605507.SH)公告称,近日,公司取得中国工商银行股份有限公司绍兴分行出具的《关于对国邦医药集团股份有限公司股票回购专项贷款项目的承诺函》,承诺贷款额度不超过1.8亿元,贷款期限3年,贷款专项用于回购公司股票。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100033680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639660429","title":"每周股票复盘:DR国邦医(605507)国邦医药推1至2亿元回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2639660429","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639660429?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:01","pubTimestamp":1780171299,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,DR国邦医报收于15.31元,较上周的22.38元下跌31.59%。本周,DR国邦医5月25日盘中最高价报22.58元。本周关注点公司公告汇总:国邦医药拟以1亿元至2亿元回购股份,用于员工持股或股权激励。公司公告汇总国邦医药拟以集中竞价交易方式回购股份,金额不低于1亿元、不超过2亿元,资金来源于自有资金及自筹资金。主要股东在未来3至6个月暂无减持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786585963749,"stockEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0378},{"period":"3month","weight":-0.0435},{"period":"6month","weight":-0.2116},{"period":"1year","weight":-0.0252},{"period":"ytd","weight":-0.0921}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0084},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0332},{"period":"1year","weight":0.0766},{"period":"ytd","weight":-0.0056}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"国邦医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20855人(较上一季度增加3.89%)","perCapita":"37513股","listingDate":"2021-08-02","address":"浙江省绍兴市新昌县省级高新技术产业园区兴梅大道60号","registeredCapital":"78235万元","survey":" 国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、“优秀院士专家工作站”、第一批浙江省制造业单项冠军企业等荣誉称号。","listedPrice":32.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国邦医药,605507,国邦医药股票,国邦医药股票老虎,国邦医药股票老虎国际,国邦医药行情,国邦医药股票行情,国邦医药股价,国邦医药股市,国邦医药股票价格,国邦医药股票交易,国邦医药股票购买,国邦医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}